{"id":29,"date":"2026-01-15T20:08:18","date_gmt":"2026-01-15T20:08:18","guid":{"rendered":"https:\/\/hirekhan.com\/blog\/?p=29"},"modified":"2026-02-20T07:51:11","modified_gmt":"2026-02-20T07:51:11","slug":"hire-xpro-america-us-fda-consultants-for-fda-direct-portals-drugs-cder-direct-cosmetics-direct-mocra-compliance","status":"publish","type":"post","link":"https:\/\/hirekhan.com\/blog\/2026\/01\/15\/hire-xpro-america-us-fda-consultants-for-fda-direct-portals-drugs-cder-direct-cosmetics-direct-mocra-compliance\/","title":{"rendered":"Hire XPRO America US FDA Consultants for FDA Direct Portals: Drugs CDER Direct &amp; Cosmetics Direct (MoCRA Compliance)"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"545\" src=\"https:\/\/hirekhan.com\/blog\/wp-content\/uploads\/2026\/01\/fda-direct-1024x545.jpg\" alt=\"\" class=\"wp-image-30\" srcset=\"https:\/\/hirekhan.com\/blog\/wp-content\/uploads\/2026\/01\/fda-direct-1024x545.jpg 1024w, https:\/\/hirekhan.com\/blog\/wp-content\/uploads\/2026\/01\/fda-direct-300x160.jpg 300w, https:\/\/hirekhan.com\/blog\/wp-content\/uploads\/2026\/01\/fda-direct-768x409.jpg 768w, https:\/\/hirekhan.com\/blog\/wp-content\/uploads\/2026\/01\/fda-direct-1536x817.jpg 1536w, https:\/\/hirekhan.com\/blog\/wp-content\/uploads\/2026\/01\/fda-direct-2048x1090.jpg 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\">Introduction: Why FDA Direct Portal Expertise Is Non-Negotiable<\/a><\/h2>\n\n\n\n<p>In today\u2019s highly regulated U.S. market,&nbsp;<strong><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\">US FDA compliance is not optional\u2014it is foundational<\/a><\/strong>. Drug manufacturers, private label distributors, outsourcing facilities, cosmetic brands, and logistics stakeholders must comply with strict federal registration, listing, and reporting obligations to legally operate in the United States.<\/p>\n\n\n\n<p>The&nbsp;<strong><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\">FDA Direct Portals<\/a><\/strong>, particularly&nbsp;<strong>CDER Direct<\/strong>&nbsp;and&nbsp;<strong>Cosmetics Direct<\/strong>, are the official electronic gateways for submitting regulatory data to the&nbsp;<strong>U.S. Food and Drug Administration<\/strong>&nbsp;and its drug division,&nbsp;<strong>Center for Drug Evaluation and Research<\/strong>.<\/p>\n\n\n\n<p>However, navigating these portals\u2014especially&nbsp;<strong><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\">Structured Product Labeling (SPL)<\/a><\/strong>,&nbsp;<strong>Drug Establishment Registration<\/strong>,&nbsp;<strong>NDC Labeler Code requests<\/strong>, and&nbsp;<strong>MoCRA cosmetic registrations<\/strong>\u2014requires deep regulatory and technical expertise. This is where&nbsp;<strong>XPRO America US FDA Consultants<\/strong>&nbsp;become a strategic partner rather than just a service provider.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\">Understanding FDA CDER Direct: The Backbone of Drug Compliance<\/a><\/h2>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/images.squarespace-cdn.com\/content\/v1\/63d73206be666022b1fe2cce\/0d259242-c4ac-4f5d-b2bf-39416646bb59\/Screenshot%2B2023-06-17%2Bat%2B11.31.22%2BAM.png\" alt=\"https:\/\/images.squarespace-cdn.com\/content\/v1\/63d73206be666022b1fe2cce\/0d259242-c4ac-4f5d-b2bf-39416646bb59\/Screenshot%2B2023-06-17%2Bat%2B11.31.22%2BAM.png\"\/><\/a><\/figure>\n\n\n\n<p>4<\/p>\n\n\n\n<p><strong><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\">CDER Direct<\/a><\/strong>&nbsp;is the FDA\u2019s centralized submission platform for drug-related regulatory obligations. It is used by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Drug manufacturers<\/li>\n\n\n\n<li>Private label distributors<\/li>\n\n\n\n<li>Generic drug facilities<\/li>\n\n\n\n<li>Outsourcing facilities (503B)<\/li>\n\n\n\n<li>Wholesale drug distributors<\/li>\n\n\n\n<li>Third-party logistics (3PL) providers<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Key CDER Direct Submission Sections<\/h3>\n\n\n\n<h4 class=\"wp-block-heading\">1. Establishment Registration &amp; Drug Listing<\/h4>\n\n\n\n<p>Every facility engaged in manufacturing, repacking, relabeling, or distributing drugs in U.S. commercial distribution must register annually with FDA and list all applicable drug products.<\/p>\n\n\n\n<p>XPRO America manages:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>FDA Establishment Registration (initial &amp; annual renewal)<\/li>\n\n\n\n<li>Drug Product Listing via SPL<\/li>\n\n\n\n<li>Updates for formulation, labeling, or manufacturing changes<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">2. NDC Labeler Code Requests &amp; Reservations<\/h4>\n\n\n\n<p>The&nbsp;<a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\"><strong>National Drug Code (NDC)<\/strong>&nbsp;<\/a>is mandatory for drugs marketed in the U.S. CDER Direct allows:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>New NDC Labeler Code applications<\/li>\n\n\n\n<li>NDC product and package code reservations<\/li>\n<\/ul>\n\n\n\n<p>Errors here can delay product launch. XPRO America ensures&nbsp;<strong>accurate SPL mapping<\/strong>, correct dosage forms, and compliant labeling hierarchies.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">3. <a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\">Outsourcing Facility &amp; Product Reporting (503B)<\/a><\/h4>\n\n\n\n<p>Outsourcing facilities must submit:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Facility registration<\/li>\n\n\n\n<li>Semiannual drug product reports<\/li>\n<\/ul>\n\n\n\n<p>XPRO America handles:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Facility classification<\/li>\n\n\n\n<li>Product SPL creation<\/li>\n\n\n\n<li>Timely FDA submissions<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">4. DSCSA Annual Reporting<\/h4>\n\n\n\n<p>Under the&nbsp;<strong>Drug Supply Chain Security Act (DSCSA)<\/strong>, manufacturers and repackagers must submit annual reports to FDA confirming compliance with traceability and supply chain integrity requirements.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">5. Generic Drug Self-Identification<\/h4>\n\n\n\n<p>Generic drug facilities must self-identify annually, linking products, ANDA references, and manufacturing roles. XPRO America ensures precise data alignment to avoid FDA discrepancies.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Structured Product Labeling (SPL): The Technical Core<\/h2>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/resource.ddregpharma.com\/wp-content\/uploads\/2023\/01\/spl-inner.png\" alt=\"https:\/\/resource.ddregpharma.com\/wp-content\/uploads\/2023\/01\/spl-inner.png\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/www.reedtech.com\/wp-content\/smush-webp\/2020\/11\/Composition-Docs-3.png.webp\" alt=\"https:\/\/www.reedtech.com\/wp-content\/smush-webp\/2020\/11\/Composition-Docs-3.png.webp\"\/><\/a><\/figure>\n\n\n\n<p>4<\/p>\n\n\n\n<p><strong>SPL is not a PDF or Word document<\/strong>\u2014it is an XML-based data standard mandated by FDA. A single tagging error can result in rejection.<\/p>\n\n\n\n<p>XPRO America provides:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>SPL authoring &amp; validation<\/li>\n\n\n\n<li>XML schema compliance<\/li>\n\n\n\n<li>FDA ESG\/CDER Direct upload support<\/li>\n\n\n\n<li>Lifecycle management for SPL updates<\/li>\n<\/ul>\n\n\n\n<p>This technical-regulatory bridge is where most companies fail without expert consultants.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Cosmetics Direct &amp; MoCRA: A New Era of Cosmetic Regulation<\/h2>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/resource.chemlinked.com.cn\/cosmetic\/articles\/fda-direct.jpg\" alt=\"https:\/\/resource.chemlinked.com.cn\/cosmetic\/articles\/fda-direct.jpg\"\/><\/a><\/figure>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/resource.chemlinked.com.cn\/cosmetic\/articles\/2-6.png\" alt=\"https:\/\/resource.chemlinked.com.cn\/cosmetic\/articles\/2-6.png\"\/><\/figure>\n\n\n\n<p>4<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\">MoCRA Legal Background<\/a><\/h3>\n\n\n\n<p>On&nbsp;<strong>December 29, 2022<\/strong>, the U.S. President signed the&nbsp;<strong>Consolidated Appropriations Act, 2023 (Pub. L. 117-328)<\/strong>&nbsp;into law. This legislation included the&nbsp;<strong>Modernization of Cosmetics Regulation Act of 2022 (MoCRA)<\/strong>, amending the&nbsp;<strong>Federal Food, Drug, and Cosmetic Act (FD&amp;C Act)<\/strong>&nbsp;by adding&nbsp;<strong>Section 607<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What MoCRA Mandates<\/h3>\n\n\n\n<p>Under MoCRA, cosmetic companies must now complete:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Cosmetic Facility Registration<\/strong>\n<ul class=\"wp-block-list\">\n<li>Manufacturers and processors (domestic &amp; foreign)<\/li>\n\n\n\n<li>Mandatory updates for ownership or location changes<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Cosmetic Product Listing<\/strong>\n<ul class=\"wp-block-list\">\n<li>Each cosmetic product marketed in the U.S.<\/li>\n\n\n\n<li>Ingredient disclosures, brand details, and manufacturing sites<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n\n\n\n<p>All submissions must be made via&nbsp;<strong>Cosmetics Direct<\/strong>, the FDA\u2019s official portal.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\">Why Hire XPRO America for Cosmetics Direct Compliance<\/a><\/h2>\n\n\n\n<p>XPRO America supports:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>MoCRA facility registration<\/li>\n\n\n\n<li>Cosmetic product listing<\/li>\n\n\n\n<li>Amendments &amp; annual updates<\/li>\n\n\n\n<li>U.S. Agent coordination for foreign manufacturers<\/li>\n<\/ul>\n\n\n\n<p>They ensure:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Correct ingredient nomenclature<\/li>\n\n\n\n<li>Alignment with FDA cosmetic definitions<\/li>\n\n\n\n<li>Error-free FDA portal submissions<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\">Coverage Across the Entire FDA-Regulated Ecosystem<\/a><\/h2>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/uploads\/sites\/24\/2024\/07\/Image-2-LOTTE-BIOLOGICS-East-Syracuse-Pharmaceutical-Manufacturing-Facility-USA.jpg\" alt=\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/uploads\/sites\/24\/2024\/07\/Image-2-LOTTE-BIOLOGICS-East-Syracuse-Pharmaceutical-Manufacturing-Facility-USA.jpg\"\/><\/a><\/figure>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/www.brookings.edu\/wp-content\/uploads\/2023\/11\/shutterstock_2210366209.jpg?quality=75&amp;w=1000\" alt=\"https:\/\/www.brookings.edu\/wp-content\/uploads\/2023\/11\/shutterstock_2210366209.jpg?quality=75&amp;w=1000\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/www.grandviewresearch.com\/static\/img\/research\/us-pharmaceutical-third-party-logistics-services-market.png\" alt=\"https:\/\/www.grandviewresearch.com\/static\/img\/research\/us-pharmaceutical-third-party-logistics-services-market.png\"\/><\/figure>\n\n\n\n<p>4<\/p>\n\n\n\n<p><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\">XPRO America works with:<\/a><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug manufacturers<\/strong>&nbsp;(innovator &amp; generic)<\/li>\n\n\n\n<li><strong>Private label distributors<\/strong><\/li>\n\n\n\n<li><strong>Outsourcing facilities (503B)<\/strong><\/li>\n\n\n\n<li><strong>Wholesale drug distributors<\/strong><\/li>\n\n\n\n<li><strong>Third-party logistics providers (3PLs)<\/strong><\/li>\n\n\n\n<li><strong>Cosmetic brands &amp; contract manufacturers<\/strong><\/li>\n<\/ul>\n\n\n\n<p>Their consultants understand how FDA evaluates&nbsp;<strong>commercial distribution status<\/strong>, facility roles, and product classifications.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/hirekhan.com\/blog\/wp-content\/uploads\/2026\/01\/XPRO-1-1024x683.png\" alt=\"US FDA Consultants, XPRO America, CDER Direct, FDA Direct Portal, Drug Establishment Registration, Drug Listing SPL, Structured Product Labeling, NDC Labeler Code, NDC Reservation, Outsourcing Facility Registration, DSCSA Annual Reporting, Generic Drug Self Identification, Cosmetics Direct, MoCRA Compliance, Cosmetic Facility Registration, Cosmetic Product Listing, US FDA CDER, FD&amp;C Act Section 607, FDA Drug Compliance Consultant, FDA Cosmetic Registration\" class=\"wp-image-1497\" srcset=\"https:\/\/hirekhan.com\/blog\/wp-content\/uploads\/2026\/01\/XPRO-1-1024x683.png 1024w, https:\/\/hirekhan.com\/blog\/wp-content\/uploads\/2026\/01\/XPRO-1-300x200.png 300w, https:\/\/hirekhan.com\/blog\/wp-content\/uploads\/2026\/01\/XPRO-1-768x512.png 768w, https:\/\/hirekhan.com\/blog\/wp-content\/uploads\/2026\/01\/XPRO-1.png 1536w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\">Why XPRO America Is a Strategic FDA Partner (Not Just a Consultant)<\/a><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">1. Direct Portal Expertise<\/h3>\n\n\n\n<p>Hands-on experience with&nbsp;<strong>CDER Direct<\/strong>&nbsp;and&nbsp;<strong>Cosmetics Direct<\/strong>, not theoretical compliance.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">2. Zero-Error Submission Philosophy<\/h3>\n\n\n\n<p>FDA rejections cost time, money, and market access. XPRO America focuses on&nbsp;<strong>first-time-right submissions<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">3. End-to-End Lifecycle Management<\/h3>\n\n\n\n<p>From initial registration to annual renewals, SPL updates, and regulatory changes.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">4. Ideal for U.S. &amp; Non-U.S. Companies<\/h3>\n\n\n\n<p>Foreign manufacturers benefit from XPRO America\u2019s&nbsp;<strong>U.S. Agent support and FDA communication handling<\/strong>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Business Impact: Compliance That Enables Revenue<\/h2>\n\n\n\n<p>FDA compliance is not a checkbox\u2014it is a&nbsp;<strong>revenue enabler<\/strong>. Without valid registrations, listings, and MoCRA filings:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Products can be detained or refused at U.S. ports<\/li>\n\n\n\n<li>Amazon, Walmart, and U.S. distributors may reject onboarding<\/li>\n\n\n\n<li>Investors and partners lose confidence<\/li>\n<\/ul>\n\n\n\n<p>Hiring XPRO America ensures your&nbsp;<strong>regulatory foundation supports scalable U.S. commercialization<\/strong>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><a href=\"http:\/\/xproamerica.com\/sales-lead\/index.php\" data-type=\"link\" data-id=\"xproamerica.com\/sales-lead\/index.php\" target=\"_blank\" rel=\"noopener\">Conclusion: Secure FDA Compliance with XPRO America<\/a><\/h2>\n\n\n\n<p>Whether you are submitting&nbsp;<strong>Drug Establishment Registration<\/strong>,&nbsp;<strong>NDC Labeler Codes<\/strong>,&nbsp;<strong>SPL drug listings<\/strong>,&nbsp;<strong>DSCSA reports<\/strong>, or&nbsp;<strong>MoCRA cosmetic registrations<\/strong>, the FDA Direct portals demand precision, experience, and accountability.<\/p>\n\n\n\n<p><strong>XPRO America US FDA Consultants<\/strong>&nbsp;provide exactly that\u2014<strong>trusted expertise for CDER Direct and Cosmetics Direct<\/strong>, ensuring your drugs and cosmetics remain compliant, market-ready, and commercially viable in the United States.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n","protected":false},"excerpt":{"rendered":"<p>Introduction: Why FDA Direct Portal Expertise Is Non-Negotiable In today\u2019s highly regulated U.S. market,&nbsp;US FDA compliance is not optional\u2014it is foundational. Drug manufacturers, private label distributors, outsourcing facilities, cosmetic brands, and logistics stakeholders must comply with strict federal registration, listing, and reporting obligations to legally operate in the United States. The&nbsp;FDA Direct Portals, particularly&nbsp;CDER Direct&nbsp;and&nbsp;Cosmetics [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[71,83,84,82,73,74,79,86,88,72,87,80,81,77,76,78,75,85,69,70],"class_list":["post-29","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-cder-direct","tag-cosmetic-facility-registration","tag-cosmetic-product-listing","tag-cosmetics-direct","tag-drug-establishment-registration","tag-drug-listing-spl","tag-dscsa-annual-reporting","tag-fdc-act-section-607","tag-fda-cosmetic-registration","tag-fda-direct-portal","tag-fda-drug-compliance-consultant","tag-generic-drug-self-identification","tag-mocra-compliance","tag-ndc-labeler-code","tag-ndc-reservation","tag-outsourcing-facility-registration","tag-structured-product-labeling","tag-us-fda-cder","tag-us-fda-consultants","tag-xpro-america"],"_links":{"self":[{"href":"https:\/\/hirekhan.com\/blog\/wp-json\/wp\/v2\/posts\/29","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hirekhan.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hirekhan.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hirekhan.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hirekhan.com\/blog\/wp-json\/wp\/v2\/comments?post=29"}],"version-history":[{"count":2,"href":"https:\/\/hirekhan.com\/blog\/wp-json\/wp\/v2\/posts\/29\/revisions"}],"predecessor-version":[{"id":1498,"href":"https:\/\/hirekhan.com\/blog\/wp-json\/wp\/v2\/posts\/29\/revisions\/1498"}],"wp:attachment":[{"href":"https:\/\/hirekhan.com\/blog\/wp-json\/wp\/v2\/media?parent=29"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hirekhan.com\/blog\/wp-json\/wp\/v2\/categories?post=29"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hirekhan.com\/blog\/wp-json\/wp\/v2\/tags?post=29"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}